Navigation Links
Use of Mealtime Pramlintide Added to Basal Insulin Showed Similar Improvements in Glycemic Control Compared to Rapid-Acting Insulin, With Lower Risk of Hypoglycemia and Without Weight Gain: Data Presented at ADA 2009
Date:6/7/2009

eline). Use of SYMLIN was not associated with weight gain.

"The effect of SYMLIN was similar to that of mealtime rapid-acting insulin when added to basal insulin treatment in this study, with SYMLIN use resulting in no weight gain and less hypoglycemia," said Dennis Karounos, staff physician and associate professor of internal medicine, Lexington Veterans Affairs Medical Center and University of Kentucky College of Medicine. "For patients recently requiring basal insulin, adding mealtime therapy with pramlintide may be a preferable alternative to mealtime rapid-acting insulin."

Phase 2 of the study (12 weeks) explored additional mealtime therapy for patients failing to achieve a target A1C of 6.5 percent or less at week 24. SYMLIN recipients not achieving target A1C (n=31) added rapid-acting insulin at week 26, while rapid-acting insulin recipients not achieving target A1C (n=36) added SYMLIN at week 26. For both combination groups, A1C and weight remained relatively stable throughout Phase 2. The addition of SYMLIN in Phase 2 for patients initially receiving rapid-acting insulin allowed a marked reduction in the amount of rapid-acting insulin used (38.6 plus or minus 3.8 U/d at week 24 vs. 19.4 plus or minus 3.2 U/d at week 36).

Patients who achieved an A1C of 6.5 percent or less at week 24 did not add an additional agent in the second phase of the study. For those patients, A1C levels were stable in both groups and no significant weight change occurred.

Patient Reported Outcomes

Additional analysis from the same study assessed patient-reported diabetes-specific quality of life (using the Diabetes Distress Scale) and treatment satisfaction (using the Diabetes Treatment Satisfaction Questionnaire) through week 24. Only SYMLIN patients experienced an improvement in total diabetes distress, while both SYMLIN and rapid-acting insulin patients experienced improvement in othe
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Mother and Daughter Create Lead-Free/Safe Bibs and Solve Messy Mealtime Problems
2. Mealtime interaction encourages hospitalized seniors to eat more
3. Corals added to IUCN Red List of Threatened Species for first time
4. Halozyme Therapeutics Added to Nasdaq Biotech Index
5. Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
6. An Event Added to Celebrate and Empower North Carolina Women
7. Blood pressure drug may have added benefit
8. VA Has Added 20 New Vet Centers
9. Turner Investment Partners Added to AHA Diversified Equity Fund
10. Kelsey Grammer, Ben Stiller, Maroon 5 and The Roots Added to COMEDY CENTRALs(R) Live On-air Charity Special Night of Too Many Stars: An Overbooked Concert for Autism Education Hosted by Jon Stewart on Sunday April 13, at 8 p.m. ET
11. IPC The Hospitalist Company Added to Russell 2000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... (PRWEB) April 21, 2015 The PracticeMatch ... from 5:00 to 8:00 pm at the William and Ida ... Hill, NC 27599. More than 50 hospitals, clinics and groups ... All specialties will be represented. Attendees will enjoy free hors ... Career Fairs for PracticeMatch says “Chapel Hill is ...
(Date:4/21/2015)... United Benefit Advisors (UBA), the nation’s ... to welcome Power Kunkle Benefits Consulting as its ... Jeff Power have been committed to providing the ... more than 450 clients. For Power Kunkle Benefits ... stewardship, ethical consulting, and measurable results. , ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Atlantic ... the launch of Medicare-Medicaid Dual Eligibles Database, a ... on care provided to the more than 9 ... account for more than $300 billion in annual ... – the same team that also creates the ...
(Date:4/21/2015)... Nashville, Tenn. – Radsource, a leader ... Archiving and Communication Systems (PACS), has expanded its ... the first quarter of 2015. , Kentucky Breast ... and Lowcountry Orthopaedics & Sports Medicine (Charleston, SC) ... services. Mt. San Rafael Hospital (Trinidad, CO) will ...
(Date:4/21/2015)... Timonium, Maryland (PRWEB) April 21, 2015 eSight ... who are legally blind to see and, on Tuesday, May ... (LVS of MD & VA) will host an unveiling ... Timonium, MD office. LVS of MD & VA will be ... eyewear. A limited number of individual patient demonstrations will be ...
Breaking Medicine News(10 mins):Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 2Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 3Health News:Power Kunkle Benefits Consulting Is the Latest Partner Firm To Join United Benefit Advisors 2Health News:New AIS Database Tracks All Programs, Plans Serving the Dual-Eligible Community 2Health News:Radsource Adds 4 ProtonPACS Clients in 1st Quarter 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 3
... Steps To Serve Your Champagne This Holiday With Style And ... Ease - And Most Importantly ... ,There,s nothing that brings a little sparkle to your holiday ... Americans will,consume more than 900 million glasses of champagne this ...
... Calif., Dec. 21 Pharmacyclics,Inc. (Nasdaq: PCYC ) ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of non-small cell lung cancer (NSCLC) patients ... combination with whole brain,radiation therapy (WBRT) was filed with ...
... 21 Biodel Inc. (Nasdaq:,BIOD) today announced that Dr. ... corporate update at the 26th Annual JPMorgan Healthcare,Conference on ... The JPMorgan Healthcare Conference will be held January ... Francisco, California., Interested parties may access a link ...
... Center receives shipment milestone - expanding, their depth ... SET technologies, IRVINE, Calif., Dec. 21 ... Read-Through Motion and Low,Perfusion pulse oximetry, today announced ... bedside pulse oximeter (excluding hand-held units) to,Alta Bates ...
... Contest Urges Young People to Promote Home,Safety, ... has named the winners of its 2008 National ... States Environmental Protection,Agency. First-place winner is Sara Garcia, ... Science in Hollywood, Florida; second-place winner is,Daniel Carr, ...
... Ireland Cancer Center of University Hospitals Case Medical Center, in ... the Cancer Research Network, found that the majority of older ... the standard of treatment five years of daily oral ... the February issue of Journal of Clinical Oncology and released ...
Cached Medicine News:Health News:Five Steps to Pop the Cork - Not Your Eye Out 2Health News:Five Steps to Pop the Cork - Not Your Eye Out 3Health News:Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases 2Health News:Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases 3Health News:Biodel Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 7th, 2008 2Health News:Biodel Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 7th, 2008 3Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 2Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 3Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 4Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 5Health News:National Safety Council Names Winners of Radon Poster Contest 2Health News:Ireland Cancer Center researcher finds standard treatment for breast cancer not followed 2
(Date:4/21/2015)... April 21, 2015  Legal-Bay LLC, The Lawsuit ... Boehringer Ingelheim Pharmaceuticals, is seeking FDA approval for ... According to PBR, Boehringer submitted a supplemental new ... that Pradaxa will be approved for the prophylaxis ... (PE) for patients who have undergone a primary ...
(Date:4/20/2015)... , April 20, 2015 Research published today ... of Sciences (PNAS) demonstrates that technology invented ... Casey Eye Institute can improve the ... Optical coherence tomography (OCT) angiography could largely replace ... diseases. OHSU researchers found that OCT ...
(Date:4/20/2015)... BILLERICA, Mass. , April 20, 2015 /PRNewswire/ ... tools for cell metabolism research, introduces the XFp ... a unique real-time assay on live cells that ... one-hour test measures both the mitochondrial and glycolytic ... values with metabolic activity under stressed conditions, induced ...
Breaking Medicine Technology:Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE 2Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE 3Study shows new technology may improve management of leading causes of blindness 2Study shows new technology may improve management of leading causes of blindness 3Study shows new technology may improve management of leading causes of blindness 4Study shows new technology may improve management of leading causes of blindness 5New XFp Cell Energy Phenotype Test Determines Metabolic Potential 2New XFp Cell Energy Phenotype Test Determines Metabolic Potential 3
... As previously announced, primary endpoint not met; ... with ERBITUX,-, NEW YORK, April 16, 2007 ... Company today,announced detailed results from the EPIC ... trial - comparing ERBITUX(R),(Cetuximab) plus irinotecan to ...
... WIRE)--Apr 17, 2007 - Curis, Inc.,(NASDAQ:CRIS), a ... primarily for cancer treatment, today announced that ... the 98th Annual Meeting,of the American Association ... also disclosed that its April 2005 discovery,collaboration ...
Cached Medicine Technology:Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 2Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 3Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 4
Aluminum english and metric ruler. 1 3/8 inche wide....
At 14 cm point, ruler is bent at 90 degrees angle brought to a blunt point at 15 cm....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: